LP
RNAC icon

LMR Partners’s Cartesian Therapeutics RNAC Stock Holding History

LMR Partners’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,236
Closed -$93.3K – 1074
2023
Q1 		$93.3K Buy
+2,236
New +$105K ﹤0.01% 947
2022
Q4 		– Sell
-1,094
Closed -$54K – 1243
2022
Q3 		$54K Hold
1,094
– – ﹤0.01% 1092
2022
Q2 		$43K Buy
+1,094
New +$32.4K ﹤0.01% 1171
2019
Q4 		– Sell
-362
Closed -$19K – 523
2019
Q3 		$19K Hold
362
– – ﹤0.01% 400
2019
Q2 		$19K Buy
+362
New +$24.7K ﹤0.01% 402

Other funds holding RNAC

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LMR Partners's RNAC Position: Q2 2023 in Review

LMR Partners sold out of Cartesian Therapeutics (RNAC) in Q2 2023, closing a stake of 2,236 shares — an estimated $93.3K sold.

LMR Partners first reported a position in RNAC in Q2 2019 and held it in 5 quarters. The position peaked at $93.3K in Q1 2023. 92 funds tracked by Wall St. Rank hold RNAC as of Q2 2023.

  • LMR Partners reported no remaining Cartesian Therapeutics position as of Q2 2023 after selling out during the quarter.
  • LMR Partners sold 2,236 Cartesian Therapeutics shares in Q2 2023, an estimated $93.3K.
  • LMR Partners first reported a position in Cartesian Therapeutics in Q2 2019 and held it in 5 quarters.
  • LMR Partners's Cartesian Therapeutics position peaked at $93.3K in Q1 2023.
  • 92 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2023.

Based on LMR Partners's 13F filing for Q2 2023, filed 14 Aug 2023.